Biomarkers | Topics

NCI-MATCH Supports Using NGS to Triage Patients to Investigational Therapy
October 21, 2020

Results from NCI-MATCH support the feasibility and efficiency of using next-generation sequencing (NGS) to triage patients to investigational therapy, provided that a sufficiently large pool of agents is made available.

Keith T. Flaherty, MD, on NCI-MATCH Supporting NGS to Triage Patients to Investigational Therapy
October 20, 2020

New research from NCI-MATCH support the feasibility and efficiency of using next-generation sequencing (NGS) to triage patients to investigational therapy, given that a sufficiently large pool of agents is provided.

FDA Grants Expanded Access Program to Ulixertinib for MAPK Pathway Aberrant Cancer
September 29, 2020

xCures recently announced that the FDA granted its IND immediate Expanded Access Program for the ERK inhibitor ulixertinib to treat patients with MAPK pathway aberrant cancer.